Trial · NCT07076095
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Frequency of adverse events (AEs) and SAEs (Phase II) | Approximately within 36 months | To investigate the safety characteristics. |
| Secondary | Pharmacokinetic (PK) Cmax (Phase II) | Approximately within 36 months | PK parameters (Cmax) following single dose. |
| Secondary | Pharmacokinetic (PK) Cmin (Phase II) | Approximately within 36 months | PK parameters (Cmin) following single dose. |
| Secondary | Pharmacokinetic (PK) Tmax (Phase II) | Approximately within 36 months | PK parameters (Tmax) following single dose. |
| Secondary | Pharmacokinetic (PK) AUC 0-t (Phase II) | Approximately within 36 months | PK parameters (AUC 0-t) following single dose. |
| Secondary | Pharmacokinetic (PK) AUC 0-∞ (Phase II) | Approximately within 36 months | PK parameters (AUC 0-∞) following single dose. |
| Secondary | Pharmacokinetic (PK) CL (Phase II) | Approximately within 36 months | PK parameters (CL) following single dose. |
| Secondary | Pharmacokinetic (PK) Vd (Phase II) | Approximately within 36 months | PK parameters (Vd) following single dose. |
| Secondary | Pharmacokinetic (PK) t1/2 (Phase II) | Approximately within 36 months | PK parameters (t1/2) following single dose. |
| Secondary | Pharmacokinetic (PK) λz (Phase II) | Approximately within 36 months | PK parameters (λz) following single dose. |
| Secondary | Pharmacokinetic (PK) Css,max (Phase II) | Approximately within 36 months | PK parameters (Css,max) following multiple dose. |
| Secondary | Pharmacokinetic (PK) Css,min (Phase II) | Approximately within 36 months | PK parameters (Css,min) following multiple dose. |
| Secondary | Pharmacokinetic (PK) Css,av (Phase II) | Approximately within 36 months | PK parameters (Css,av) following multiple dose. |
| Secondary | Pharmacokinetic (PK) AUCss (Phase II) | Approximately within 36 months | PK parameters (AUCss) following multiple dose. |
| Secondary | Pharmacokinetic (PK) CLss (Phase II) | Approximately within 36 months | PK parameters (CLss) following multiple dose. |
| Secondary | Pharmacokinetic (PK) Vss (Phase II) | Approximately within 36 months | PK parameters (Vss) following multiple dose. |
| Secondary | Pharmacokinetic (PK) R (Phase II) | Approximately within 36 months | PK parameters (R) following multiple dose. |
| Secondary | Pharmacokinetic (PK) DF (Phase II) | Approximately within 36 months | PK parameters (DF) following multiple dose. |
| Secondary | Incidence of Anti-Drug Antibodies (ADA)(Phase II) | Approximately within 36 months | |
| Secondary | Overall survival (OS) (Phase II) | Baseline through up to 2 years or until disease progression | OS as assessed using RECIST 1.1. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07076095/registered